Genmab A/S (GMAB) Stock Forecast & Price Target $20.47 +0.02 (+0.10%) (As of 11/21/2024 ET) Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2024) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating Moderate BuyBased on 10 Analyst RatingsSell1Hold2Buy7 Based on 10 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a sell rating, 2 have given a hold rating, and 7 have given a buy rating for GMAB. Consensus Price Target $45.20120.81% Upside According to the 10 analysts' twelve-month price targets for Genmab A/S, the average price target is $45.20. The highest price target for GMAB is $50.00, while the lowest price target for GMAB is $31.00. The average price target represents a forecasted upside of 120.81% from the current price of $20.47. Get the Latest News and Ratings for GMAB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors. Enter your email to sign up for newsletter Sign Up GMAB Analyst Ratings Over TimeTypeCurrent Forecast11/23/23 to 11/22/241 Month Ago10/24/23 to 10/23/243 Months Ago8/25/23 to 8/24/241 Year Ago11/23/22 to 11/23/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy7 Buy rating(s)9 Buy rating(s)8 Buy rating(s)8 Buy rating(s)Hold2 Hold rating(s)2 Hold rating(s)2 Hold rating(s)5 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)3 Sell rating(s)2 Sell rating(s)Consensus Price Target$45.20$45.20$49.50$46.25Forecasted Upside120.81% Upside98.86% Upside81.05% Upside46.59% UpsideConsensus RatingModerate BuyModerate BuyHoldHold What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.Click here now to watch the full briefing and discover the steps to take today. GMAB Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History GMAB Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Genmab A/S Stock vs. The CompetitionTypeGenmab A/SMedical CompaniesS&P 500Consensus Rating Score 2.60 2.80 2.50Consensus RatingModerate BuyModerate BuyModerate BuyPredicted Upside120.81% Upside26,390.75% Upside8.55% UpsideNews Sentiment RatingPositive NewsSee Recent GMAB NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails11/8/2024BMO Capital Markets4 of 5 stars Reiterated RatingOutperform ➝ Outperform$46.00 ➝ $48.00+110.25%10/16/2024HC Wainwright2 of 5 stars Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00+115.70%10/8/2024Redburn Atlantic0 of 5 starsQ. DingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy9/11/2024Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingEqual Weight ➝ Equal Weight$31.00 ➝ $31.00+15.63%9/9/2024Truist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$53.00 ➝ $50.00+82.55%8/20/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Neutral Get the Latest News and Ratings for GMAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. 7/15/2024Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingA. CampbellSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Perform ➝ Outperform6/27/2024BTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$46.00 ➝ $47.00+83.09%1/22/2024CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeNeutral ➝ Sell12/6/2023UBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeNeutral ➝ Buy11/10/2023Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeHold ➝ Buy11/8/2023DNB MarketsSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeSell ➝ Buy10/18/2023BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageUnderperform10/12/2023Nordea Equity ResearchSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeBuy ➝ Hold7/14/2023HSBCSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy2/23/2023DanskeSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeHold ➝ Buy2/6/2023Leerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetMarket Perform$33.00 ➝ $36.00-5.91%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:50 AM ET. Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 31, 2024. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com. Genmab A/S Bull Case Here are some ways that investors could benefit from investing in Genmab A/S: Genmab A/S has shown resilience in the market with a stable 50-day moving average price of $27.19, indicating consistent performance in the short term. The company has a strong market capitalization of $18.16 billion, reflecting its size and stability in the industry. Genmab A/S has a low P/E ratio of 22.88, suggesting that the stock may be undervalued compared to its earnings potential. Analysts predict a positive EPS of 1.21 for the current year, indicating potential growth and profitability for investors. Genmab A/S has a diverse portfolio of antibody therapeutics for cancer and other diseases, offering potential for significant advancements in healthcare. Genmab A/S Bear Case Investors should be bearish about investing in Genmab A/S for these reasons: Genmab A/S stock has experienced a decline in its 12-month high from $38.80 to $27.46, indicating potential volatility and downside risk. The company reported earnings per share (EPS) below analysts' estimates, which may raise concerns about its ability to meet financial expectations. Genmab A/S has a beta of 0.99, suggesting that the stock's price movements are closely linked to the overall market, potentially leading to higher volatility. Despite positive ratings from analysts, there are sell ratings on the stock, indicating differing opinions on its future performance. Investors should consider the competitive landscape in the biopharmaceutical industry, which may impact Genmab A/S' market position and growth prospects. GMAB Forecast - Frequently Asked Questions What is Genmab A/S's forecast for 2025? According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $45.20, with a high forecast of $50.00 and a low forecast of $31.00. Should I buy or sell Genmab A/S stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There is currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GMAB shares. Does Genmab A/S's stock price have much upside? According to analysts, Genmab A/S's stock has a predicted upside of 120.81% based on their 12-month stock forecasts. What analysts cover Genmab A/S? Genmab A/S has been rated by research analysts at BMO Capital Markets, HC Wainwright, Morgan Stanley, Redburn Atlantic, and Truist Financial in the past 90 days. Do Wall Street analysts like Genmab A/S more than its competitors? Analysts like Genmab A/S less than other "medical" companies. The consensus rating score for Genmab A/S is 2.60 while the average consensus rating score for "medical" companies is 2.80. Learn more on how GMAB compares to other companies. Stock Forecasts and Research Tools Related Companies BioNTech Stock Forecast Teva Pharmaceutical Industries Stock Forecast BeiGene Stock Forecast Viatris Stock Forecast Moderna Stock Forecast Summit Therapeutics Stock Forecast Dr. Reddy's Laboratories Stock Forecast Vaxcyte Stock Forecast Catalent Stock Forecast Sarepta Therapeutics Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.Click here now to watch the full briefing and discover the steps to take today. This page (NASDAQ:GMAB) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GMAB Stock Alerts